Stock Events

enGene 

$8.74
2
-$0.18-2.02% Today

Statistics

Day High
-
Day Low
-
52W High
43
52W Low
6.69
Volume
145,248
Avg. Volume
158,438
Mkt Cap
385.79M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

14JunConfirmed
Q4 2023
Q1 2024
-0.46
-0.4
-0.35
-0.29
Expected EPS
-0.29
Actual EPS
-0.38

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENGN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap122.46B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other diseases, overlapping with enGene's focus on gene therapy for gastrointestinal diseases.
Sangamo Therapeutics
SGMO
Mkt Cap66.92M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, which competes directly with enGene's gene therapy technologies.
CRISPR Therapeutics
CRSP
Mkt Cap4.51B
CRISPR Therapeutics is known for its work in CRISPR-Cas9 gene editing, a technology that can be applied similarly to enGene's gene delivery platforms.
Bluebird bio
BLUE
Mkt Cap100.95M
bluebird bio operates in the gene therapy space focusing on genetic diseases and cancer, areas that are potential targets for enGene's technologies.
Intellia Therapeutics
NTLA
Mkt Cap2.2B
Intellia Therapeutics is another key player in the CRISPR gene editing sector, directly competing with enGene's approach to gene therapy.
Biomarin Pharmaceutical
BMRN
Mkt Cap15.47B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, similar to enGene's market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.75B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, a field closely related to gene therapy, impacting similar therapeutic areas as enGene.
Ionis Pharmaceuticals
IONS
Mkt Cap6.73B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, competing in the broader genetic medicine space with enGene.
uniQure N.V.
QURE
Mkt Cap186.43M
uniQure is involved in developing gene therapies for patients with severe genetic diseases, directly competing with enGene's therapeutic approaches.
Regenxbio
RGNX
Mkt Cap536.89M
REGENXBIO is a biotechnology company specializing in the development of gene therapy products, competing in the same innovative sector as enGene.

Analyst Ratings

34.4$Average Price Target
The highest estimate is $40.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Show more...
CEO
Employees
31
Country
CA
ISIN
CA29286M1059

Listings